↓ Skip to main content

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Overview of attention for article published in Journal of Clinical Oncology, June 2019
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Readers on

mendeley
386 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Published in
Journal of Clinical Oncology, June 2019
DOI 10.1200/jco.19.01009
Pubmed ID
Authors

Krishnansu S Tewari, Robert A Burger, Danielle Enserro, Barbara M Norquist, Elizabeth M Swisher, Mark F Brady, Michael A Bookman, Gini F Fleming, Helen Huang, Howard D Homesley, Jeffrey M Fowler, Benjamin E Greer, Matthew Boente, Sharon X Liang, Chenglin Ye, Carlos Bais, Leslie M Randall, John K Chan, J Stuart Ferriss, Robert L Coleman, Carol Aghajanian, Thomas J Herzog, Philip J DiSaia, Larry J Copeland, Robert S Mannel, Michael J Birrer, Bradley J Monk

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 89 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 386 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 386 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Other 44 11%
Researcher 40 10%
Student > Master 29 8%
Student > Ph. D. Student 21 5%
Student > Bachelor 20 5%
Other 59 15%
Unknown 173 45%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 111 29%
Biochemistry, Genetics and Molecular Biology 33 9%
Agricultural and Biological Sciences 12 3%
Pharmacology, Toxicology and Pharmaceutical Science 9 2%
Nursing and Health Professions 8 2%
Other 27 7%
Unknown 186 48%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 130. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 July 2025.
All research outputs
#407,053
of 34,451,315 outputs
Outputs from Journal of Clinical Oncology
#774
of 32,387 outputs
Outputs of similar age
#6,727
of 399,128 outputs
Outputs of similar age from Journal of Clinical Oncology
#18
of 740 outputs
Altmetric has tracked 34,451,315 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,387 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.4. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 399,128 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 740 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.